| Bioactivity | SBI-477 is a chemical probe stimulated insulin signaling by deactivating the transcription factor MondoA, leading to reduced expression of the insulin pathway suppressors thioredoxin-interacting protein (TXNIP) and arrestin domain–containing 4 (ARRDC4). SBI-477 coordinately inhibits triacylglyceride (TAG) synthesis and enhances basal glucose uptake in human skeletal myocytes[1]. | ||||||||||||
| Target | MondoA | ||||||||||||
| Name | SBI-477 | ||||||||||||
| CAS | 781628-99-7 | ||||||||||||
| Formula | C24H25N3O6S | ||||||||||||
| Molar Mass | 483.54 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Ahn B, et al. MondoA coordinately regulates skeletal myocyte lipid homeostasis and insulin signaling. J Clin Invest. 2016 Sep 1;126(9):3567-79. |
SBI-477
CAS: 781628-99-7 F: C24H25N3O6S W: 483.54
SBI-477 is a chemical probe stimulated insulin signaling by deactivating the transcription factor MondoA, leading to red
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.